Tyrosine kinase inhibitorFDA-approvedFirst-line
Dacomitinib
How it works
Blocks the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
In clinical trials, around 50% of EGFR-mutated patients achieved an objective response, with median progression-free survival of approximately 14 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Paronychia and Skin Rash in Lung Cancer Patient Treated with Dacomitinib | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.